SlideShare une entreprise Scribd logo
1  sur  32
Presented By,
Group No-01
Animesh Amal(01)
Madhura Jagtap(10)
Bosco James(15)
Shafaatali(18)
Bhavika Sachdev(23)
Contents
 Introduction
 Objective
 Research Design
PIMARY INVESTIGATION
COLLECTION OF QUANTITATIVE DATA
SAMPLING PROCESS
FIELD WORK
DATA ANALYSIS PLAN
 Findings
 Chi-Square analysis
 Conclusion
 References
Introduction
• Stem cells are biological cells found in all
multicellular organisms, that can divide (through
mitosis) and differentiate into diverse specialized
cell types and can self-renew to produce more
stem cells.
• In mammals, there are two broad types of stem
cells:
• Embryonic stem cells, which are isolated from the
inner cell mass of blastocysts and
• Adult stem cells, which are found in various
tissues
Introduction
• Stem cell research in India is in a healthy state.
• This is mainly due to the fact that scientists and physicians
have taken deep interest in harnessing the benefits.
• India is emerging as a potential player for developing stem
cell therapy and is currently in the list of top ten countries
that are heavily engaged in stem cell research.
• Major Asian economies are also expected to attract better
investments in stem cell industry and India is expected to
be in the forefront with a market growth potential with a
compound annual growth rate (CAGR) of 25 percent or
more by 2015.
Source- Indian express, By Dr Anish Majumdar, 03rd October 2012, 10:30 AM
Objectives
• To study the market of stem cells.
• To know about the awareness level of stem
cells.
Research Design
DATA ANALYSIS PLAN
6415
14
10
Age
Sample Size-103
Gender
4360
Sample Size-103
Education
4551
7
Sample Size-103
Occupation
4917
11
1610
Sample Size-103
Awareness of Stem Cell therapy
65
16
22
Sample Size-103
Awareness of the potential benefits
6620
17
Sample Size-103
Ethical or not
5413
36
Sample Size-103
preservation
43
13
47
Sample Size-103
Support Of family member
67
36
Sample Size-103
Source of information
42
21
15
25
Sample Size-103
Chi-square analysis
• Awareness Vs Gender
Awareness * Gender Crosstabulation
Gender Total
Male Female
Awareness
Yes
Count 42 25 67
Expected Count 39.0 28.0 67.0
No
Count 7 7 14
Expected Count 8.2 5.8 14.0
Slightly
Count 11 11 22
Expected Count 12.8 9.2 22.0
Total
Count 60 43 103
Expected Count 60.0 43.0 103.0
Chi-Square Tests
Value df Asymp. Sig. (2-
sided)
Pearson Chi-Square 1.550a 2 .461
Likelihood Ratio 1.542 2 .462
Linear-by-Linear Association 1.345 1 .246
N of Valid Cases 103
a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is
5.84.
Here Sig value is >0.05
So Null hypothesis is accepted,
There is no relationship between Awareness and Gender
Awareness Vs Age
Awareness * Age Crosstabulation
Age Total
25-30 31-35 36-40 41-45
Awareness
Yes
Count 46 8 10 3 67
Expected
Count 41.6 9.8 9.1 6.5 67.0
No
Count 8 2 1 3 14
Expected
Count 8.7 2.0 1.9 1.4 14.0
Slightly
Count 10 5 3 4 22
Expected
Count 13.7 3.2 3.0 2.1 22.0
Total
Count 64 15 14 10 103
Expected
Count 64.0 15.0 14.0 10.0 103.0
Chi-Square Tests
Value df Asymp. Sig. (2-
sided)
Pearson Chi-Square 8.836a 6 .183
Likelihood Ratio 8.515 6 .203
Linear-by-Linear Association 4.310 1 .038
N of Valid Cases 103
a. 6 cells (50.0%) have expected count less than 5. The minimum expected count
is 1.36.
Here Sig value is >0.05
So Null hypothesis is accepted,
There is no relationship between Awareness and Age
Awareness Vs Occupation
Awareness * Occupation Crosstabulation
Occupation Total
Student Self
empl.
Gov emp. Non gov
empl.
Other
Awareness
Yes
Count 35 10 7 7 8 67
Expected
Count
31.9 11.1 7.2 6.5 10.4 67.0
No
Count 6 4 1 0 3 14
Expected
Count
6.7 2.3 1.5 1.4 2.2 14.0
Slightly
Count 8 3 3 3 5 22
Expected
Count
10.5 3.6 2.3 2.1 3.4 22.0
Total
Count 49 17 11 10 16 103
Expected
Count
49.0 17.0 11.0 10.0 16.0 103.0
Chi-Square Tests
Value df Asymp. Sig. (2-
sided)
Pearson Chi-Square 6.096a 8 .636
Likelihood Ratio 7.176 8 .518
Linear-by-Linear Association 2.283 1 .131
N of Valid Cases 103
a. 8 cells (53.3%) have expected count less than 5. The minimum expected count is
1.36.
Here Sig value is >0.05
So Null hypothesis is accepted,
There is no relationship between Awareness and Occupation
Awareness Vs Education
Awareness * Education Crosstabulation
Education Total
Under
Graduate
Graduate Post
graduate
Awareness
Yes
Count 3 25 39 67
Expected
Count 4.6 29.3 33.2 67.0
No
Count 2 8 4 14
Expected
Count 1.0 6.1 6.9 14.0
Slightly
Count 2 12 8 22
Expected
Count 1.5 9.6 10.9 22.0
Total
Count 7 45 51 103
Expected
Count 7.0 45.0 51.0 103.0
Chi-Square Tests
Value df Asymp. Sig. (2-
sided)
Pearson Chi-Square 6.684a 4 .154
Likelihood Ratio 6.646 4 .156
Linear-by-Linear Association 4.358 1 .037
N of Valid Cases 103
a. 3 cells (33.3%) have expected count less than 5. The minimum expected count is
.95.
Here Sig value is >0.05
So Null hypothesis is accepted,
There is no relationship between Awareness and Education
Awareness Vs Income
Awareness * Income Crosstabulation
Income Total
Less than
1lac
1-3lac 3-5lac More
than 5lac
5lac
Awareness
Yes
Count 30 16 9 12 0 67
Expected
Count 31.9 20.2 5.9 8.5 .7 67.0
No
Count 4 9 0 0 1 14
Expected
Count 6.7 4.2 1.2 1.8 .1 14.0
Slightly
Count 15 6 0 1 0 22
Expected
Count 10.5 6.6 1.9 2.8 .2 22.0
Total
Count 49 31 9 13 1 103
Expected
Count 49.0 31.0 9.0 13.0 1.0 103.0
Chi-Square Tests
Value df Asymp. Sig. (2-
sided)
Pearson Chi-Square 25.074a 8 .002
Likelihood Ratio 26.247 8 .001
Linear-by-Linear Association 5.404 1 .020
N of Valid Cases 103
a. 8 cells (53.3%) have expected count less than 5. The minimum expected count
is .14.
Here Sig value is <0.05
So Alternative hypothesis is accepted,
There is a relationship between Awareness and Income
Conclusion
• Several top level academic institutions as well as industries
in the biotechnology sphere are actively carrying out
research in the area of stem cell biology and therapy.
• The growing interest is also evidenced by a recent surge in
clinical trials using various types of stem cells against a
variety of indications including cardiac, vascular, arthritis,
gastro-intestinal, pulmonary, respiratory and neural
diseases.
• India is an emerging player in this field
• the number of companies engaged in some kind of stem
cell research has topped over 100, and about 30-40 of
these are actively pursuing stem cell based clinical trials for
bringing it to the market in the next 3-5 years.
References
• Indian express, By Dr Anish Majumdar, 03rd
October 2012 10:30 AM
• http://www.sciencedaily.com/articles/s/stem_
cell_treatments.htm
• http://www.medicalnewstoday.com/sections/
stem_cell/
• http://science.nationalgeographic.com/scienc
e/health-and-human-body/human-
body/stem-cell-divide/
Market research on Stem cell

Contenu connexe

Tendances

De Finetti meets Popper
De Finetti meets PopperDe Finetti meets Popper
De Finetti meets Popper
Stephen Senn
 
What should we expect from reproducibiliry
What should we expect from reproducibiliryWhat should we expect from reproducibiliry
What should we expect from reproducibiliry
Stephen Senn
 
Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...
Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...
Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...
cambridgeWD
 

Tendances (14)

What is your question
What is your questionWhat is your question
What is your question
 
De Finetti meets Popper
De Finetti meets PopperDe Finetti meets Popper
De Finetti meets Popper
 
What should we expect from reproducibiliry
What should we expect from reproducibiliryWhat should we expect from reproducibiliry
What should we expect from reproducibiliry
 
Personalised medicine a sceptical view
Personalised medicine a sceptical viewPersonalised medicine a sceptical view
Personalised medicine a sceptical view
 
Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...
Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...
Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...
 
The revenge of RA Fisher
The revenge of RA FisherThe revenge of RA Fisher
The revenge of RA Fisher
 
First in man tokyo
First in man tokyoFirst in man tokyo
First in man tokyo
 
Thinking statistically v3
Thinking statistically v3Thinking statistically v3
Thinking statistically v3
 
PS.Observational.SAS_Y.Duan
PS.Observational.SAS_Y.DuanPS.Observational.SAS_Y.Duan
PS.Observational.SAS_Y.Duan
 
Biostatistics Workshop: Regression
Biostatistics Workshop: RegressionBiostatistics Workshop: Regression
Biostatistics Workshop: Regression
 
Numbers needed to mislead
Numbers needed to misleadNumbers needed to mislead
Numbers needed to mislead
 
P value wars
P value warsP value wars
P value wars
 
On being Bayesian
On being BayesianOn being Bayesian
On being Bayesian
 
Response heterigeneity and Replicated Crossover Trials
Response heterigeneity and Replicated Crossover TrialsResponse heterigeneity and Replicated Crossover Trials
Response heterigeneity and Replicated Crossover Trials
 

En vedette

Galvus kol slide deck 2011 pcc approved
Galvus kol slide deck 2011 pcc approvedGalvus kol slide deck 2011 pcc approved
Galvus kol slide deck 2011 pcc approved
Dr. Lin
 
The Challenge of getting things done
The Challenge of getting things doneThe Challenge of getting things done
The Challenge of getting things done
Deep Bhandari
 
Monopolistic competition in short run
Monopolistic competition in short runMonopolistic competition in short run
Monopolistic competition in short run
Animesh Gupta
 
Tivo in 2005 strategic inflection lt4 rev 01
Tivo in 2005 strategic inflection lt4 rev 01Tivo in 2005 strategic inflection lt4 rev 01
Tivo in 2005 strategic inflection lt4 rev 01
Madhur Gopal
 
Ims report on m health october 2013
Ims report on m health october 2013Ims report on m health october 2013
Ims report on m health october 2013
Madhur Gopal
 
Product Mix of Dr. Reddy's
Product Mix of Dr. Reddy'sProduct Mix of Dr. Reddy's
Product Mix of Dr. Reddy's
Animesh Gupta
 
Brand Plan for the launch of Brand-X
Brand Plan for the launch of Brand-XBrand Plan for the launch of Brand-X
Brand Plan for the launch of Brand-X
Satyajit Hui
 

En vedette (20)

Coupon code
Coupon codeCoupon code
Coupon code
 
Neoslim™ Final
Neoslim™ FinalNeoslim™ Final
Neoslim™ Final
 
Galvus kol slide deck 2011 pcc approved
Galvus kol slide deck 2011 pcc approvedGalvus kol slide deck 2011 pcc approved
Galvus kol slide deck 2011 pcc approved
 
Resource card (esn, moocs, mobile & micro learning, social on boarding)
Resource card (esn, moocs, mobile & micro learning, social on boarding)Resource card (esn, moocs, mobile & micro learning, social on boarding)
Resource card (esn, moocs, mobile & micro learning, social on boarding)
 
Subprime lt4
Subprime lt4Subprime lt4
Subprime lt4
 
Philippines World Bank Report 2013
Philippines World Bank Report 2013Philippines World Bank Report 2013
Philippines World Bank Report 2013
 
Team building - S.Babu
Team building - S.BabuTeam building - S.Babu
Team building - S.Babu
 
Mamma ki pari
Mamma ki pariMamma ki pari
Mamma ki pari
 
Nokia symbian strategy
Nokia symbian strategyNokia symbian strategy
Nokia symbian strategy
 
Gamification Guidelines
Gamification GuidelinesGamification Guidelines
Gamification Guidelines
 
Fundamental Questions for Leaders
Fundamental Questions for LeadersFundamental Questions for Leaders
Fundamental Questions for Leaders
 
Performance grid saikat.jpg
Performance grid saikat.jpgPerformance grid saikat.jpg
Performance grid saikat.jpg
 
The Challenge of getting things done
The Challenge of getting things doneThe Challenge of getting things done
The Challenge of getting things done
 
Mobile Learning Case Study
Mobile Learning Case StudyMobile Learning Case Study
Mobile Learning Case Study
 
Engage 9 Blocks Business Model case study
Engage 9 Blocks Business Model case studyEngage 9 Blocks Business Model case study
Engage 9 Blocks Business Model case study
 
Monopolistic competition in short run
Monopolistic competition in short runMonopolistic competition in short run
Monopolistic competition in short run
 
Tivo in 2005 strategic inflection lt4 rev 01
Tivo in 2005 strategic inflection lt4 rev 01Tivo in 2005 strategic inflection lt4 rev 01
Tivo in 2005 strategic inflection lt4 rev 01
 
Ims report on m health october 2013
Ims report on m health october 2013Ims report on m health october 2013
Ims report on m health october 2013
 
Product Mix of Dr. Reddy's
Product Mix of Dr. Reddy'sProduct Mix of Dr. Reddy's
Product Mix of Dr. Reddy's
 
Brand Plan for the launch of Brand-X
Brand Plan for the launch of Brand-XBrand Plan for the launch of Brand-X
Brand Plan for the launch of Brand-X
 

Similaire à Market research on Stem cell

Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...
Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...
Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...
cambridgeWD
 
Practical Methods To Overcome Sample Size Challenges
Practical Methods To Overcome Sample Size ChallengesPractical Methods To Overcome Sample Size Challenges
Practical Methods To Overcome Sample Size Challenges
nQuery
 
Measuring clinical utility: uncertainty in Net Benefit
Measuring clinical utility: uncertainty in Net BenefitMeasuring clinical utility: uncertainty in Net Benefit
Measuring clinical utility: uncertainty in Net Benefit
Laure Wynants
 
2012-michael joiner-hypofractionation
2012-michael joiner-hypofractionation2012-michael joiner-hypofractionation
2012-michael joiner-hypofractionation
fondas vakalis
 
Sampling 1231243290208505 1
Sampling 1231243290208505 1Sampling 1231243290208505 1
Sampling 1231243290208505 1
guest7e772ec
 

Similaire à Market research on Stem cell (20)

Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...
Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...
Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...
 
Lecture # 10 chi-square test of association
Lecture # 10  chi-square test of associationLecture # 10  chi-square test of association
Lecture # 10 chi-square test of association
 
Mean platelet volume and other platelet volume indices in patients with acute...
Mean platelet volume and other platelet volume indices in patients with acute...Mean platelet volume and other platelet volume indices in patients with acute...
Mean platelet volume and other platelet volume indices in patients with acute...
 
Journal Club - Discussion of Heriot et al. Criteria for identifying patients ...
Journal Club - Discussion of Heriot et al. Criteria for identifying patients ...Journal Club - Discussion of Heriot et al. Criteria for identifying patients ...
Journal Club - Discussion of Heriot et al. Criteria for identifying patients ...
 
Practical Methods To Overcome Sample Size Challenges
Practical Methods To Overcome Sample Size ChallengesPractical Methods To Overcome Sample Size Challenges
Practical Methods To Overcome Sample Size Challenges
 
Chi square test
Chi square testChi square test
Chi square test
 
Automated hematology analyzer as a cost effective aid to screen and monitor s...
Automated hematology analyzer as a cost effective aid to screen and monitor s...Automated hematology analyzer as a cost effective aid to screen and monitor s...
Automated hematology analyzer as a cost effective aid to screen and monitor s...
 
Kshivets O. Gastric Cancer Relapse Surgery
Kshivets O. Gastric Cancer Relapse SurgeryKshivets O. Gastric Cancer Relapse Surgery
Kshivets O. Gastric Cancer Relapse Surgery
 
Collaborative Database and Computational Models for Tuberculosis Drug Discovery
Collaborative Database and Computational Models for Tuberculosis Drug DiscoveryCollaborative Database and Computational Models for Tuberculosis Drug Discovery
Collaborative Database and Computational Models for Tuberculosis Drug Discovery
 
Measuring clinical utility: uncertainty in Net Benefit
Measuring clinical utility: uncertainty in Net BenefitMeasuring clinical utility: uncertainty in Net Benefit
Measuring clinical utility: uncertainty in Net Benefit
 
PSB 2018 presentation
PSB 2018 presentationPSB 2018 presentation
PSB 2018 presentation
 
Critical appraisal of a journal article
Critical appraisal of a journal articleCritical appraisal of a journal article
Critical appraisal of a journal article
 
2012-michael joiner-hypofractionation
2012-michael joiner-hypofractionation2012-michael joiner-hypofractionation
2012-michael joiner-hypofractionation
 
Chi squared test
Chi squared test Chi squared test
Chi squared test
 
Sampling 1231243290208505 1
Sampling 1231243290208505 1Sampling 1231243290208505 1
Sampling 1231243290208505 1
 
Sampling in Statistical Inference
Sampling in Statistical InferenceSampling in Statistical Inference
Sampling in Statistical Inference
 
Chapter12
Chapter12Chapter12
Chapter12
 
Internal examination 3rd semester disaster
Internal examination 3rd semester disasterInternal examination 3rd semester disaster
Internal examination 3rd semester disaster
 
Sign Test
Sign TestSign Test
Sign Test
 
Imatinib vs. 2nd gen TKI in newly diagnosed Chronic Myelogenous Leukemia 
Imatinib vs. 2nd gen TKI in newly diagnosed Chronic Myelogenous Leukemia Imatinib vs. 2nd gen TKI in newly diagnosed Chronic Myelogenous Leukemia 
Imatinib vs. 2nd gen TKI in newly diagnosed Chronic Myelogenous Leukemia 
 

Plus de Animesh Gupta (11)

Brand plan on cough syrup
Brand plan on cough syrup Brand plan on cough syrup
Brand plan on cough syrup
 
Marketing Plan of Esomeprazole
Marketing Plan of EsomeprazoleMarketing Plan of Esomeprazole
Marketing Plan of Esomeprazole
 
Marketing plan of Shampoo
Marketing plan of ShampooMarketing plan of Shampoo
Marketing plan of Shampoo
 
Diffusion and adoption of innovation
Diffusion and adoption of innovationDiffusion and adoption of innovation
Diffusion and adoption of innovation
 
Market research on Health drinks in india
Market research on Health drinks in indiaMarket research on Health drinks in india
Market research on Health drinks in india
 
Macleods
MacleodsMacleods
Macleods
 
Product Mix of Novartis
Product Mix of NovartisProduct Mix of Novartis
Product Mix of Novartis
 
Insulin
InsulinInsulin
Insulin
 
Drug absorption
Drug absorption Drug absorption
Drug absorption
 
Subprime crisis
Subprime crisisSubprime crisis
Subprime crisis
 
Product mix of amway
Product mix of amwayProduct mix of amway
Product mix of amway
 

Dernier

The basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptxThe basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptx
heathfieldcps1
 

Dernier (20)

Interdisciplinary_Insights_Data_Collection_Methods.pptx
Interdisciplinary_Insights_Data_Collection_Methods.pptxInterdisciplinary_Insights_Data_Collection_Methods.pptx
Interdisciplinary_Insights_Data_Collection_Methods.pptx
 
Fostering Friendships - Enhancing Social Bonds in the Classroom
Fostering Friendships - Enhancing Social Bonds  in the ClassroomFostering Friendships - Enhancing Social Bonds  in the Classroom
Fostering Friendships - Enhancing Social Bonds in the Classroom
 
Graduate Outcomes Presentation Slides - English
Graduate Outcomes Presentation Slides - EnglishGraduate Outcomes Presentation Slides - English
Graduate Outcomes Presentation Slides - English
 
How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17
 
On National Teacher Day, meet the 2024-25 Kenan Fellows
On National Teacher Day, meet the 2024-25 Kenan FellowsOn National Teacher Day, meet the 2024-25 Kenan Fellows
On National Teacher Day, meet the 2024-25 Kenan Fellows
 
This PowerPoint helps students to consider the concept of infinity.
This PowerPoint helps students to consider the concept of infinity.This PowerPoint helps students to consider the concept of infinity.
This PowerPoint helps students to consider the concept of infinity.
 
Jamworks pilot and AI at Jisc (20/03/2024)
Jamworks pilot and AI at Jisc (20/03/2024)Jamworks pilot and AI at Jisc (20/03/2024)
Jamworks pilot and AI at Jisc (20/03/2024)
 
SKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptx
SKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptxSKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptx
SKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptx
 
Beyond_Borders_Understanding_Anime_and_Manga_Fandom_A_Comprehensive_Audience_...
Beyond_Borders_Understanding_Anime_and_Manga_Fandom_A_Comprehensive_Audience_...Beyond_Borders_Understanding_Anime_and_Manga_Fandom_A_Comprehensive_Audience_...
Beyond_Borders_Understanding_Anime_and_Manga_Fandom_A_Comprehensive_Audience_...
 
Food safety_Challenges food safety laboratories_.pdf
Food safety_Challenges food safety laboratories_.pdfFood safety_Challenges food safety laboratories_.pdf
Food safety_Challenges food safety laboratories_.pdf
 
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptx
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptxHMCS Max Bernays Pre-Deployment Brief (May 2024).pptx
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptx
 
Unit-V; Pricing (Pharma Marketing Management).pptx
Unit-V; Pricing (Pharma Marketing Management).pptxUnit-V; Pricing (Pharma Marketing Management).pptx
Unit-V; Pricing (Pharma Marketing Management).pptx
 
REMIFENTANIL: An Ultra short acting opioid.pptx
REMIFENTANIL: An Ultra short acting opioid.pptxREMIFENTANIL: An Ultra short acting opioid.pptx
REMIFENTANIL: An Ultra short acting opioid.pptx
 
80 ĐỀ THI THỬ TUYỂN SINH TIẾNG ANH VÀO 10 SỞ GD – ĐT THÀNH PHỐ HỒ CHÍ MINH NĂ...
80 ĐỀ THI THỬ TUYỂN SINH TIẾNG ANH VÀO 10 SỞ GD – ĐT THÀNH PHỐ HỒ CHÍ MINH NĂ...80 ĐỀ THI THỬ TUYỂN SINH TIẾNG ANH VÀO 10 SỞ GD – ĐT THÀNH PHỐ HỒ CHÍ MINH NĂ...
80 ĐỀ THI THỬ TUYỂN SINH TIẾNG ANH VÀO 10 SỞ GD – ĐT THÀNH PHỐ HỒ CHÍ MINH NĂ...
 
The basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptxThe basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptx
 
Towards a code of practice for AI in AT.pptx
Towards a code of practice for AI in AT.pptxTowards a code of practice for AI in AT.pptx
Towards a code of practice for AI in AT.pptx
 
2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx
2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx
2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx
 
ICT role in 21st century education and it's challenges.
ICT role in 21st century education and it's challenges.ICT role in 21st century education and it's challenges.
ICT role in 21st century education and it's challenges.
 
How to setup Pycharm environment for Odoo 17.pptx
How to setup Pycharm environment for Odoo 17.pptxHow to setup Pycharm environment for Odoo 17.pptx
How to setup Pycharm environment for Odoo 17.pptx
 
Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...
Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...
Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...
 

Market research on Stem cell

  • 1. Presented By, Group No-01 Animesh Amal(01) Madhura Jagtap(10) Bosco James(15) Shafaatali(18) Bhavika Sachdev(23)
  • 2. Contents  Introduction  Objective  Research Design PIMARY INVESTIGATION COLLECTION OF QUANTITATIVE DATA SAMPLING PROCESS FIELD WORK DATA ANALYSIS PLAN  Findings  Chi-Square analysis  Conclusion  References
  • 3. Introduction • Stem cells are biological cells found in all multicellular organisms, that can divide (through mitosis) and differentiate into diverse specialized cell types and can self-renew to produce more stem cells. • In mammals, there are two broad types of stem cells: • Embryonic stem cells, which are isolated from the inner cell mass of blastocysts and • Adult stem cells, which are found in various tissues
  • 4. Introduction • Stem cell research in India is in a healthy state. • This is mainly due to the fact that scientists and physicians have taken deep interest in harnessing the benefits. • India is emerging as a potential player for developing stem cell therapy and is currently in the list of top ten countries that are heavily engaged in stem cell research. • Major Asian economies are also expected to attract better investments in stem cell industry and India is expected to be in the forefront with a market growth potential with a compound annual growth rate (CAGR) of 25 percent or more by 2015. Source- Indian express, By Dr Anish Majumdar, 03rd October 2012, 10:30 AM
  • 5. Objectives • To study the market of stem cells. • To know about the awareness level of stem cells.
  • 7.
  • 8.
  • 9.
  • 14. Awareness of Stem Cell therapy 65 16 22 Sample Size-103
  • 15. Awareness of the potential benefits 6620 17 Sample Size-103
  • 18. Support Of family member 67 36 Sample Size-103
  • 20. Chi-square analysis • Awareness Vs Gender Awareness * Gender Crosstabulation Gender Total Male Female Awareness Yes Count 42 25 67 Expected Count 39.0 28.0 67.0 No Count 7 7 14 Expected Count 8.2 5.8 14.0 Slightly Count 11 11 22 Expected Count 12.8 9.2 22.0 Total Count 60 43 103 Expected Count 60.0 43.0 103.0
  • 21. Chi-Square Tests Value df Asymp. Sig. (2- sided) Pearson Chi-Square 1.550a 2 .461 Likelihood Ratio 1.542 2 .462 Linear-by-Linear Association 1.345 1 .246 N of Valid Cases 103 a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 5.84. Here Sig value is >0.05 So Null hypothesis is accepted, There is no relationship between Awareness and Gender
  • 22. Awareness Vs Age Awareness * Age Crosstabulation Age Total 25-30 31-35 36-40 41-45 Awareness Yes Count 46 8 10 3 67 Expected Count 41.6 9.8 9.1 6.5 67.0 No Count 8 2 1 3 14 Expected Count 8.7 2.0 1.9 1.4 14.0 Slightly Count 10 5 3 4 22 Expected Count 13.7 3.2 3.0 2.1 22.0 Total Count 64 15 14 10 103 Expected Count 64.0 15.0 14.0 10.0 103.0
  • 23. Chi-Square Tests Value df Asymp. Sig. (2- sided) Pearson Chi-Square 8.836a 6 .183 Likelihood Ratio 8.515 6 .203 Linear-by-Linear Association 4.310 1 .038 N of Valid Cases 103 a. 6 cells (50.0%) have expected count less than 5. The minimum expected count is 1.36. Here Sig value is >0.05 So Null hypothesis is accepted, There is no relationship between Awareness and Age
  • 24. Awareness Vs Occupation Awareness * Occupation Crosstabulation Occupation Total Student Self empl. Gov emp. Non gov empl. Other Awareness Yes Count 35 10 7 7 8 67 Expected Count 31.9 11.1 7.2 6.5 10.4 67.0 No Count 6 4 1 0 3 14 Expected Count 6.7 2.3 1.5 1.4 2.2 14.0 Slightly Count 8 3 3 3 5 22 Expected Count 10.5 3.6 2.3 2.1 3.4 22.0 Total Count 49 17 11 10 16 103 Expected Count 49.0 17.0 11.0 10.0 16.0 103.0
  • 25. Chi-Square Tests Value df Asymp. Sig. (2- sided) Pearson Chi-Square 6.096a 8 .636 Likelihood Ratio 7.176 8 .518 Linear-by-Linear Association 2.283 1 .131 N of Valid Cases 103 a. 8 cells (53.3%) have expected count less than 5. The minimum expected count is 1.36. Here Sig value is >0.05 So Null hypothesis is accepted, There is no relationship between Awareness and Occupation
  • 26. Awareness Vs Education Awareness * Education Crosstabulation Education Total Under Graduate Graduate Post graduate Awareness Yes Count 3 25 39 67 Expected Count 4.6 29.3 33.2 67.0 No Count 2 8 4 14 Expected Count 1.0 6.1 6.9 14.0 Slightly Count 2 12 8 22 Expected Count 1.5 9.6 10.9 22.0 Total Count 7 45 51 103 Expected Count 7.0 45.0 51.0 103.0
  • 27. Chi-Square Tests Value df Asymp. Sig. (2- sided) Pearson Chi-Square 6.684a 4 .154 Likelihood Ratio 6.646 4 .156 Linear-by-Linear Association 4.358 1 .037 N of Valid Cases 103 a. 3 cells (33.3%) have expected count less than 5. The minimum expected count is .95. Here Sig value is >0.05 So Null hypothesis is accepted, There is no relationship between Awareness and Education
  • 28. Awareness Vs Income Awareness * Income Crosstabulation Income Total Less than 1lac 1-3lac 3-5lac More than 5lac 5lac Awareness Yes Count 30 16 9 12 0 67 Expected Count 31.9 20.2 5.9 8.5 .7 67.0 No Count 4 9 0 0 1 14 Expected Count 6.7 4.2 1.2 1.8 .1 14.0 Slightly Count 15 6 0 1 0 22 Expected Count 10.5 6.6 1.9 2.8 .2 22.0 Total Count 49 31 9 13 1 103 Expected Count 49.0 31.0 9.0 13.0 1.0 103.0
  • 29. Chi-Square Tests Value df Asymp. Sig. (2- sided) Pearson Chi-Square 25.074a 8 .002 Likelihood Ratio 26.247 8 .001 Linear-by-Linear Association 5.404 1 .020 N of Valid Cases 103 a. 8 cells (53.3%) have expected count less than 5. The minimum expected count is .14. Here Sig value is <0.05 So Alternative hypothesis is accepted, There is a relationship between Awareness and Income
  • 30. Conclusion • Several top level academic institutions as well as industries in the biotechnology sphere are actively carrying out research in the area of stem cell biology and therapy. • The growing interest is also evidenced by a recent surge in clinical trials using various types of stem cells against a variety of indications including cardiac, vascular, arthritis, gastro-intestinal, pulmonary, respiratory and neural diseases. • India is an emerging player in this field • the number of companies engaged in some kind of stem cell research has topped over 100, and about 30-40 of these are actively pursuing stem cell based clinical trials for bringing it to the market in the next 3-5 years.
  • 31. References • Indian express, By Dr Anish Majumdar, 03rd October 2012 10:30 AM • http://www.sciencedaily.com/articles/s/stem_ cell_treatments.htm • http://www.medicalnewstoday.com/sections/ stem_cell/ • http://science.nationalgeographic.com/scienc e/health-and-human-body/human- body/stem-cell-divide/